These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 37758559)
21. Revisiting Intermittent Therapy in Metastatic Prostate Cancer: Can Less Be More in the "New World Order"? Shevach J; Sydes MR; Hussain M Eur Urol Focus; 2019 Mar; 5(2):125-133. PubMed ID: 30803926 [TBL] [Abstract][Full Text] [Related]
22. Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma. Sciarra A; Monti S; Gentile V; Mariotti G; Cardi A; Voria G; Lucera R; Di Silverio F Prostate; 2003 May; 55(3):168-79. PubMed ID: 12692782 [TBL] [Abstract][Full Text] [Related]
23. Intermittent androgen deprivation therapy may prolong the duration of androgen dependence of well-differentiated prostate cancer. Kaneko Y; Maekawa S; Arakaki R; Okada Y; Terada N; Nishimura K Hinyokika Kiyo; 2006 Apr; 52(4):259-64. PubMed ID: 16686352 [TBL] [Abstract][Full Text] [Related]
24. Is time to castration resistant prostate cancer a potential intermediate end-point for time to metastasis among men initiating androgen deprivation therapy for non-metastatic prostate cancer with rapid PSA doubling time (<9 months)? Klaassen Z; Howard L; Wallis CJD; Janes JL; De Hoedt A; Aronson WJ; Polascik TJ; Amling CJ; Kane CJ; Cooperberg MR; Terris MK; Wu Y; Freedland SJ Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):151-155. PubMed ID: 36050455 [TBL] [Abstract][Full Text] [Related]
25. Does race predict the development of metastases in men who receive androgen-deprivation therapy for a biochemical recurrence after radical prostatectomy? Vidal AC; Howard LE; De Hoedt A; Kane CJ; Terris MK; Aronson WJ; Cooperberg MR; Amling CL; Lechpammer S; Flanders SC; Freedland SJ Cancer; 2019 Feb; 125(3):434-441. PubMed ID: 30427535 [TBL] [Abstract][Full Text] [Related]
26. Opposing impact of hypertension/diabetes following hormone therapy initiation and preexisting statins on castration resistant progression of nonmetastatic prostate cancer: a multicenter study. Hayashi T; Miyamoto T; Iwane S; Fujitani M; Uchitani K; Koizumi Y; Hirata A; Kinoshita H; Kawabata A Sci Rep; 2024 Oct; 14(1):23119. PubMed ID: 39367145 [TBL] [Abstract][Full Text] [Related]
27. [Hormonal therapy for prostate cancer: methods and prognosis]. Huang BX; Su HC; Cao WL; Sun FK Zhonghua Nan Ke Xue; 2013 Sep; 19(9):815-9. PubMed ID: 24386861 [TBL] [Abstract][Full Text] [Related]
28. [Risk factors for early castration-resistant prostate cancer after androgen deprivation therapy for bone-metastatic prostate cancer]. Huang FM; Li XH; Liang Y Zhonghua Nan Ke Xue; 2018 Aug; 24(8):690-694. PubMed ID: 30173426 [TBL] [Abstract][Full Text] [Related]
29. Effectiveness of Adding Docetaxel to Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer in Korean Real-World Practice. Park K; Kim JY; Park I; Shin SH; Lee HJ; Lee JL Yonsei Med J; 2023 Feb; 64(2):86-93. PubMed ID: 36719015 [TBL] [Abstract][Full Text] [Related]
30. Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database. Keto CJ; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ BJU Int; 2012 Aug; 110(4):492-8. PubMed ID: 22094083 [TBL] [Abstract][Full Text] [Related]
32. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. Abrahamsson PA Eur Urol; 2010 Jan; 57(1):49-59. PubMed ID: 19683858 [TBL] [Abstract][Full Text] [Related]
33. [Availability of Local Therapy to Castration-Resistant Prostate Cancer for M0 Patients with Initial Prostate Specific Antigen 100 ng/ml or Higher]. Kuromoto A; Tanaka T; Koyama J; Goto T; Kimura S; Katsumata Y; Myoen S; Ozawa M; Morozumi K; Sato M; Hoshi S; Numahata K; Arai Y Hinyokika Kiyo; 2017 Dec; 63(12):515-520. PubMed ID: 29370662 [TBL] [Abstract][Full Text] [Related]
34. Factors predicting progression to castrate-resistant prostate cancer in patients with advanced prostate cancer receiving long-term androgen-deprivation therapy. de la Taille A; Martínez-Piñeiro L; Cabri P; Houchard A; Schalken J; BJU Int; 2017 Jan; 119(1):74-81. PubMed ID: 26919403 [TBL] [Abstract][Full Text] [Related]
37. Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12 years of follow-up. Studer UE; Whelan P; Wimpissinger F; Casselman J; de Reijke TM; Knönagel H; Loidl W; Isorna S; Sundaram SK; Collette L; Eur Urol; 2014 Nov; 66(5):829-38. PubMed ID: 23932338 [TBL] [Abstract][Full Text] [Related]
38. Mass spectrometry redefines optimal testosterone thresholds in prostate cancer patients undergoing androgen deprivation therapy. Beck J; Rouleau M; Lemire F; Neveu B; Déry M; Thériault B; Dubois G; Guérette D; Pouliot F Prostate; 2023 May; 83(7):670-677. PubMed ID: 36851864 [TBL] [Abstract][Full Text] [Related]
39. Population-based Assessment of Intermittent Androgen Deprivation Therapy Utilization for Relapsed, Nonmetastatic, Hormone-sensitive Adenocarcinoma of the Prostate. Janzen BW; Ong A; Penner M; Koul R; Dubey A; Ahmed S; Bashir B; Chowdhury A; Dawe DE; Nayak J; Kim JO Am J Clin Oncol; 2020 Dec; 43(12):865-871. PubMed ID: 32976179 [TBL] [Abstract][Full Text] [Related]
40. Prediction of Time to Castration-Resistant Prostate Cancer Using Bone Scan Index in Men with Metastatic Hormone-Sensitive Prostate Cancer. Miyoshi Y; Yoneyama S; Kawahara T; Hattori Y; Teranishi JI; Ohta JI; Takebayashi S; Yokomizo Y; Hayashi N; Uemura H Urol Int; 2017; 99(4):400-405. PubMed ID: 28609769 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]